Clinical Trial Update: A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

View source ↗

Summary

This clinical trial update describes a prospective cohort study evaluating the efficacy and safety of guselkumab in combination with JAK inhibitors for difficul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Guselkumab (guselkumab)
• JAK inhibitors (class)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Inflamatory Bowel Disease | Status: RECRUITING